Summary
Gilead Sciences, Inc. (GILD) filed an 8-K on April 20, 2009, reporting on the company's financial obligations. The primary event disclosed is Gilead's draw-down of $400 million under its existing Amended and Restated Credit Agreement to partially fund the acquisition of CV Therapeutics, Inc. This action demonstrates Gilead's strategy to utilize existing credit lines for strategic acquisitions. The company intends to repay this debt through operational cash flow, indicating confidence in its ongoing business performance.
Key Highlights
- 1Gilead Sciences drew $400 million from its Amended and Restated Credit Agreement on April 14, 2009.
- 2The borrowed funds are intended to partially finance the acquisition of CV Therapeutics, Inc.
- 3The company plans to repay the $400 million loan using cash generated from its operations.
- 4The Credit Agreement allows for aggregate borrowings of up to $1.25 billion in revolving credit loans.
- 5The Credit Agreement bears interest at LIBOR plus a margin or the base rate.
- 6The Credit Agreement matures on December 17, 2012.
- 7The filing references the original Credit Agreement filed on December 19, 2007, for further details.